TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:46
Avalo Therapeutics Inc. ( AVTX ) https://www.avalotx.com
9.09USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-23.17%
AVTX
SPY
32.66%
-99.81%
AVTX
SPY
108.59%
-99.94%
AVTX
SPY
302.52%
AVTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
67.43
-12.80
0.09
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-8.47
39.69
2.97
-50.13
0.00
0.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-5165.06
-186.75
-6820.18
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.3744
-387.11
-492.72
0.83
Other Earnings and Cash Flow Stats:
Avalo Therapeutics Inc. ( AVTX ) Net Income TTM ($MM) is -7.96
Avalo Therapeutics Inc. ( AVTX ) Operating Income TTM ($MM) is -59.18
Avalo Therapeutics Inc. ( AVTX ) Owners' Earnings Annual ($MM) is -31.30
Avalo Therapeutics Inc. ( AVTX ) Current Price to Owners' Earnings ratio is -0.08
Avalo Therapeutics Inc. ( AVTX ) EBITDA TTM ($MM) is -59.03
Avalo Therapeutics Inc. ( AVTX ) EBITDA Margin is -6820.18%
Capital Allocation:
Avalo Therapeutics Inc. ( AVTX ) has paid 0.00 dividends per share and bought back -7.45845 million shares in the past 12 months
Avalo Therapeutics Inc. ( AVTX ) has reduced its debt by 0.359 million USD in the last 12 months
Capital Structure:
Avalo Therapeutics Inc. ( AVTX ) Interest-bearing Debt ($MM) as of last quarter is 1
Avalo Therapeutics Inc. ( AVTX ) Annual Working Capital Investments ($MM) are 1
Avalo Therapeutics Inc. ( AVTX ) Book Value ($MM) as of last quarter is 22
Avalo Therapeutics Inc. ( AVTX ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
Avalo Therapeutics Inc. ( AVTX ) has 81 million in cash on hand as of last quarter
Avalo Therapeutics Inc. ( AVTX ) has 60 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Avalo Therapeutics Inc. ( AVTX ) has 7 common shares outstanding as of last quarter
Avalo Therapeutics Inc. ( AVTX ) has 0 million USD of preferred stock value
Academic Scores:
Avalo Therapeutics Inc. ( AVTX ) Altman Z-Score is -6.19 as of last quarter
Avalo Therapeutics Inc. ( AVTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Avalo Therapeutics Inc. ( AVTX ) largest shareholder is Wells Fargo & Co owning 1241 shares at 0.01 ($MM) value
Almenoff June Sherie(an insider) Bought 500 shares of Avalo Therapeutics Inc. ( AVTX ) for the amount of $6500.00 on 2024-11-13
1.76% of Avalo Therapeutics Inc. ( AVTX ) is held by insiders, and 39.21% is held by institutions
Avalo Therapeutics Inc. ( AVTX ) went public on 2015-11-13
Other Avalo Therapeutics Inc. ( AVTX ) financial metrics:
FCF:-37.09
Unlevered Free Cash Flow:-45.88
EPS:51.46
Operating Margin:-5165.06
Gross Profit Margin:-186.75
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:437.22
Beta:0.83
Buffet's Owners Earnings:-31.30
Price to Owner's Earnings:-0.08
About Avalo Therapeutics Inc. ( AVTX ) :
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.